Compositions, devices, kits and methods are disclosed for assaying triglyceride with a glycerol 3-phosphate oxidase mutant. The glycerol 3-phosphate oxidase mutant has reduced oxidase activity while substantially maintaining, or increasing, its dehydrogenase activity, compared to the wild-type glycerol 3-phosphate oxidase.

A lipolysis device that includes: a base material having a first surface and a second surface opposite the first surface; a glycerol introduction portion on the first surface of the base material, the glycerol introduction portion having a protrusion containing a lipolytic enzyme or a peptide compound having equivalent activity to that of the lipolytic enzyme; and a glycerol oxidation portion on the second surface of the base material, the glycerol oxidation portion containing glycerol oxidase that oxidizes glycerol introduced from the glycerol introduction portion.

An apparatus and method of detecting components in a microfluidic sample. The sample and a plurality of microbeads are mixed within the microfluidic device. Each of the microbeads comprises a plurality of bioactive proteins bound thereon. A fluorescent signal is generated from a reaction of the microbeads and the microfluidic sample. The generated fluorescent signal is then able to be detected, wherein an intensity of fluorescence is directly proportional to a concentration of the peroxide generated.

A method for quantifying cardiolipin in a sample, comprises the steps of: (1) treating the sample with phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase and (2) measuring the fluorescence intensity, absorbance, or luminescence intensity of a compound generated in step (1) to quantify cardiolipin using a calibration curve obtained beforehand; and a kit for quantifying cardiolipin comprises phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase.

Compositions, devices, kits and methods are disclosed for assaying triglyceride with a glycerol 3-phosphate oxidase mutant. The glycerol 3-phosphate oxidase mutant has reduced oxidase activity while substantially maintaining, or increasing, its dehydrogenase activity, compared to the wild-type glycerol 3-phosphate oxidase.

The inventions disclosed herein are a method for quantifying cardiolipin in a sample, comprising the steps of: (1) treating the sample with phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase and (2) measuring the fluorescence intensity, absorbance, or luminescence intensity of a compound generated in step (1) to quantify cardiolipin using a calibration curve obtained beforehand; and a kit for quantifying cardiolipin comprising phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase.